河北医科大学学报

• 论著 • 上一篇    下一篇

黄连素联合阿托伐他汀对急性缺血性脑卒中的临床疗效分析及其对血清炎症因子的调控作用

  

  1. 河北省保定市第一中心医院神经内三科,河北 保定 071000
  • 出版日期:2017-06-25 发布日期:2017-06-22
  • 作者简介:王佩(1971-),女,河北石家庄人,河北省保定市第 一中心医院主任医师,医学博士,从事神经内科疾病诊治研究。
  • 基金资助:
    河北省中医药管理局科研计划项目(2017307)

The analysis of clinical effect of berberine combined with atorvastatin on patients with acute #br# cerebral ischemic stroke and the regulating effect on serum inflammatory factors

  1. Third Department of Neurology, the First Center Hospital of Baoding City,
    Hebei Province, Baoding 071000, China
  • Online:2017-06-25 Published:2017-06-22

摘要: [摘要]目的探讨黄连素联合阿托伐他汀对急性缺血性脑卒中(acute cerebral ischemic stroke,AIS)的临床疗效及其对血清炎症因子巨噬细胞移动抑制因子(macrophage migration inhibitory factor,MIF)、白细胞介素6(interleukin6,IL6)及单核细胞比率(monocyte proportion,MONO%)的调控作用。方法选择120例AIS患者,随机分为联合组(n=60)和阿托伐他汀组(n=60)。2组均给予AIS常规治疗。联合组给予黄连素(300 mg,3次/d)+阿托伐他汀(40 mg,每晚1次),阿托伐他汀组给予阿托伐他汀(40 mg,每晚1次)。对2组治疗前后血清MIF、IL6、MONO%水平和美国国立卫生研究院卒中量表(National Institute of Health Stroke Scale,NIHSS)评分以及治疗90 d改良Rankin量表(Modified Rankin Scale,mRS)评分进行比较。结果 治疗前2组MIF、IL6和MONO%差异无统计学意义(P>005);治疗14 d,2组MIF、IL6和MONO%均较治疗前明显降低(P<005),且联合组MIF、IL6和MONO%明显低于阿托伐他汀组,差异有统计学意义(P<005);治疗前2组 NIHSS评分差异无统计学意义(P>005), 治疗14 d,2组NIHSS评分均明显降低(P<005),且联合组NIHSS评分明显低于阿托伐他汀组(P<005);治疗90 d,联合组mRS评分明显低于阿托伐他汀组,差异有统计学意义(P<005);治疗前2组MIF、IL6、MONO%与NIHSS评分呈正相关(P<005)。结论在AIS治疗中,黄连素联合阿托伐他汀可显著促进神经功能恢复,改善短期预后,并显著降低AIS急性期血清炎症因子MIF、IL6、MONO%水平。

关键词: 卒中, 黄连素, 白细胞介素6, 细胞迁移分析

Abstract: [Abstract] ObjectiveTo investigate the clinical effect of berberine combined with atorvastatin on patients with acute cerebral ischemic stroke(AIS) and the regulating effect on serum macrophage migration inhibitory factor(MIF), interleukin6(IL6) and monocyte proportion(MONO%). MethodsOne hundred and twenty patients with AIS were recruited and randomly divided into 2 groups: combined group(n=60) and atorvastatin group(n=60). They all received the basical treatment of AIS. Combined group received berberine(300 mg, tid) and atorvastatin(40 mg, qn). Atorvastatin group received atorvastatin(40 mg, qn). The levels of serum MIF, IL6, MONO%(before treatment and after treatment) and the nerve function defect grades(before treatment、after treatment and day 90) were measured and compared. ResultsThe levels of serum MIF, IL6 and MONO% were no significant differences between the two groups before treatment(P>005). After 14 days treatment, the levels of serum MIF, IL6 and MONO% of the two groups were significantly lower(P<005). And the levels of serum MIF, IL6 and MONO% of combined group after treatment were significantly lower than those of atorvastatin group(P<005). The National Institute of Health Stroke Scale(NIHSS) scores was no significant difference between the two groups before treatment(P>005). After 14 days treatment, the NIHSS scores of the two groups were significantly lower(P<005). And the NIHSS scores of combined group after treatment were significantly lower than those of atorvastatin group(P<005). On day 90, the Modified Rankin Scale(mRS) scores of combined group were significantly lower than those of atorvastatin group(P<005). There was positive correlation of serum MIF, IL6, MONO% and NIHSS scores before treatment(P<005). ConclusionCombined berberine with atorvastatin can significantly improve neurological impairment and downregulate the levels of serum MIF, IL6 and MONO% of patients with acute cerebral ischemic stroke.

Key words: stroke, berberine, interleukin6, cell migration assay